Advocacy Action Center

Communicating with our elected officials is an important way in which people with lymphoma and their caregivers and loved ones can champion increased support for lymphoma research and federal efforts to improve cancer care in the United States.

Urge Your Representatives to Protect Immune Compromised Community Against COVID-19

On January 18, the Lymphoma Research Foundation (LRF) sent a letter to President Biden and federal health policy and scientific leadership to urge additional actions to protect immune-compromised individuals against the risks of COVID-19, including people with lymphoma and chronic lymphocytic leukemia (CLL). Click here to read the letter.

As the letter outlines, important strides have been made in the development of COVID-19 vaccines and therapies. Throughout the pandemic, the Foundation has supplied the lymphoma community with updated information and education programs. LRF’s Lymphoma and COVID-19 Panel has communicated with healthcare professionals and patients who are immune compromised regarding risk mitigation, vaccination, and new treatments.  The panel now urges action to increase the availability of these treatments for immunocompromised individuals. 

You can help LRF make the voice of the lymphoma and CLL community heard by sharing the letter with your elected representatives using the template letter below. Don’t forget to personalize your letter and explain why this issue is important to you!

Urge Your Representatives to Grant Access to Critical Diagnostics: Sponsor HR 3772

On July 16, 2019, Rep. Scott Peters (CA-52) and Rep. Bobby Rush (IL-01), along with Rep. George Holding (NC-02), introduced the bipartisan Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (HR 3772). The bill would expand patient access to highly targeted, precision diagnostic radiopharmaceuticals that evaluate conditions such as Alzheimer’s disease, Parkinson’s disease, and some cancers—allowing patients to get the right treatment faster.

The new bill would ensure that hospitals receive adequate Medicare reimbursement to cover the high-value, low-volume diagnostic radiopharmaceuticals that are used in these nuclear medicine procedures, correcting a flawed payment philosophy and leaving hospitals free to perform the nuclear medicine procedures that patients need. To help ensure the equitable payment of diagnostic radiopharmaceuticals in the Hospital Outpatient Prospective Payment System, you can send a letter of support to your member of Congress.